GYRE Subsidiary Submits New Drug Application for Lead Candidate F351 (Hydronidone) in China
Summary
Gyre Therapeutics' subsidiary submitted a New Drug Application (NDA) for its lead product candidate, F351 (Hydronidone), in China for chronic hepatitis B-induced liver fibrosis.
Key Events
-
NDA Submission for Lead Candidate
Gyre Pharmaceuticals Co., Ltd., a majority indirectly owned subsidiary of Gyre Therapeutics, Inc., submitted a New Drug Application (NDA) to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration for F351 (Hydronidone).
-
Targeting Liver Fibrosis in China
The NDA seeks approval for F351 (Hydronidone) for the treatment of chronic hepatitis B (CHB)-induced liver fibrosis, addressing a significant medical need in the Chinese market.
-
Advancing Regulatory Pathway
This submission represents a critical regulatory milestone for the company's lead product candidate, following previously reported successful Phase 3 clinical trial results.
-
Initiation of Review Process
The NDA will undergo initial formatting and completeness verification, with the company anticipating an acceptance number from the CDE before the technical review process begins.
Analysis
This 8-K reports a significant regulatory milestone for Gyre Therapeutics. The submission of a New Drug Application (NDA) for F351 (Hydronidone), the company's lead product candidate, in China for chronic hepatitis B-induced liver fibrosis, marks a critical step towards potential commercialization. This follows the successful Phase 3 results for Hydron previously detailed in the company's 10-K filed on March 13, 2026. While regulatory approval is not guaranteed and the process is subject to CDE review, the NDA submission itself de-risks the development pathway and provides a clear path forward for the drug in a major market.
At the time of this filing, GYRE was trading at $6.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $610.8M. The 52-week trading range was $6.11 to $11.78. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.